The role of B lymphocytes in coxsackievirus B3 infection

American Journal of Pathology

Volumn 155, Issue 4, 1999, Pages 1205-1215

  Mena, Ignacio ^a   Perry, Chris M ^a   Harkins, Stephanie ^a   Rodriguez, Fernando ^a   Gebhard, John ^b   Whitton, J Lindsay ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Pharmadigm   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; COXSACKIE VIRUS B; HELPER CELL; HISTOPATHOLOGY; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRUS DETECTION;

EID: 0032883930     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65223-6     Document Type: Article

References (43)

1. Hyypia T, Kallajoki M, Maaronen M, Stanway G, Kandolf R, Auvinen P, Kalimo H: Pathogenetic differences between coxsackie A and B virus infections in newborn mice. Virus Res 1993, 27:71-78
2. Gravanis MB, Sternby NH: Incidence of myocarditis: a 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 1991, 115: 390-392
3. Misbah SA, Spickett GP, Ryba PC, Hockaday JM, Kroll JS, Sherwood C, Kurtz JB, Moxon ER, Chapel HM: Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol 1992, 12:266-270
4. McKinney REJ, Kate SL, Wilfert CM: Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1967, 9:334-356
5. Geller TJ, Condie D: A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 1995, 129:131-133
6. Hertel NT, Pedersen FK, Heilmann C: Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia. Eur J Pediatr 1989, 148:642-643
7. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM: Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 1996, 70:4632-4645
8. Klingel K, Stephan S, Sauter M, Zell R, McManus BM, Bultmann B, Kandolf R: Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol 1996, 70:8888-8895
9. Bendinelli M, Ruschi A, Campa M, Toniolo A: Depression of humoral and cell-mediated immune responses by coxsackieviruses in mice. Experientia 1975, 31:1227-1229
10. Bendinelli M, Matteucci D, Toniolo A, Patane AM, Pistillo MP: Impairment of immunocompetent mouse spleen cell functions by infection with coxsackievirus B3. J Infect Dis 1982, 146:797-805
11. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber SA: A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996, 70:7811-7818
12. Kitamura D, Roes J, Kuhn R, Rajewsky K: A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350:423-426
13. Lane TE, Paoletti AD, Buchmeier MJ: Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J Virol 1997, 71:2202-2210
14. Cao Y, Schnurr DP: Persistent infection of YAC-1 cells by coxsackievirus B3. J Gen Virol 1988, 69:59-65
15. Schnurr DP, Schmidt NJ: Persistent infection of mouse fibroblasts with coxsackievirus. Arch Virol 1984, 81:91-101
16. Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M: Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 1985, 56: 651-654
17. Anderson DR, Carthy CM, Wilson JE, Yang D, Devine DV, McManus BM: Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. J Virol 1997, 71:8841-8845
18. Bergelson JM, Chan M, Solomon KR, St. John NF, Lin H, Finberg RW: Decay-accelerating factor (CD55). a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 1994, 91:6245-6249
19. Bergelson JM, Mohanty JG, Crowell RL, St. John NF, Lublin DM, Finberg RW: Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 1995, 69:1903-1906
20. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD: Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995, 69:3873-3877
21. Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD: Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997, 71:4736-4743
22. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323
23. Shafren DR, Williams DT, Barry RD: A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 1997, 71:9844-9848
24. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW: The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998, 72:415-419
25. Henke A, Huber SA, Stelzner A, Whitton JL: The role of CD8+ T lymphocytes in coxsackie virus B3-induced myocarditis. J Virol 1995, 69:6720-6728
26. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL: Coxsackievirus 63-induced myocarditis: perform exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998, 153:417-428
27. Asano MS, Ahmed R: CD8 T cell memory in B cell-deficient mice. J Exp Med 1996, 183:2165-2174
28. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R: Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992, 89:314-318
29. Klingel K, Rieger P, Mall G, Selinka HC, Huber M, Kandolf R: Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Lab Invest 1998, 78:1227-1237
30. Planz O, Seiler P, Hengartner H, Zinkernagel RM: Specific cytotoxic T cells eliminate cells producing neutralizing antibodies. Nature 1996, 382:726-729
31. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K: The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol 1996, 70:5143-5152
32. Tomko RP, Xu R, Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses, Proc Natl Acad Sci USA 1997, 94:3352-3356
33. Heck CF, Shumway SJ, Kaye MP: The Registry of the International Society for Heart Transplantation: sixth official report 1989. J Heart Transplant 1939, 8:271-276
34. Editorial: dilated cardiomyopathy and enteroviruses. Lancet 1990, 336:971-973
35. Wolfgram LJ, Beisel KW, Rose NR Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J Exp Med 1985, 161:1112-1121
36. Neu N, Ploier B, Ofner C: Cardiac myosin-induced myocarditis: heart autoantibodies are not involved in the induction of the disease. J Immunol 1990, 145:4094-4100
37. Sato S, Tsutsumi R, Burke A, Carlson G, Porro V, Seko Y, Okumura K, Kawana R, Virmani R: Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions. J Gen Virol 1994, 75:2911-2924
38. Schnurr DP, Cao Y, Schmidt NJ: Coxsackievirus 83 persistence, and myocarditis in N:NIH(S) II nu/nu, and +/nu mice. J Gen Virol 1984, 65:1197-1201
39. Tam PE, Schmidt AM, Ytterberg SR, Messner RP: Duration of virus persistence and its relationship to inflammation in the chronic phase of coxsackievirus B1-induced murine polymyositis. J Lab Clin Med 1994, 123:346-356
40. Muir P, Archard LC: There is evidence for persistent enterovirus infections in chronic medical conditions in humans. Rev Med Virol 1994, 4:245-250
41. Melchers W, Zoll J, van Kuppeveld F, Swanink C, Galama J: There is no evidence for persistent enterovirus infections in chronic medical conditions in humans. Rev Med Virol 1994, 4:235-243
42. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA: Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998, 36: 2893-2899
43. Homann D, Tishon A, Berger DP, Weigle WO, von Herrath MG, Oldstone MBA: Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from μm MT/μm MT mice. J Virol 1998, 72:9203-9216